Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (Gülhane)
- Development stage
- Unknown
- Lead developer
- Gulhane School of Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intra-arterial
01
Overview
Autologous adipose-derived mesenchymal stem cells (AD-MSCs) are an investigational cell therapy developed by Saglik Bilimleri Universitesi Gulhane Tip Fakultesi for the treatment of liver cirrhosis secondary to chronic Hepatitis C virus (HCV) infection. The therapy involves harvesting mesenchymal stem cells from the patient's own adipose tissue, followed by expansion and repeated re-infusion. The treatment protocol utilizes a dual-route administration: a portion of the cells is delivered intravenously via a peripheral vein, while a larger dose is administered directly into the right hepatic artery. The therapeutic rationale is based on the ability of MSCs to migrate to damaged liver tissue and exert immunomodulatory, anti-inflammatory, and pro-regenerative effects, potentially promoting hepatocyte regeneration and reducing fibrosis as an alternative to liver transplantation.
- Other names
- AD-MSCsautologous adipose-derived mesenchymal stem cellsadipose tissue-derived autologous mesenchymal stem cells
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (Gülhane).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Gülhane).